Synonyms: Compound A [WO2022174269A1] | KT474
Compound class:
Synthetic organic
Comment: KT-474 is a PROTAC degrader of interleukin 1 receptor associated kinase 4 (IRAK4). It is in Kymera Therapeutics' pipeline and is initially being developed for potential to treat the autoimmune conditions atopic dermatitis and hidradenitis suppurativa [2]. A thalidomide analogue moiety is employed to direct the bound IRAK4 to the ubiquitin-proteasome pathway via the thalidomide-cereblon interaction.
|
|
Bioactivity Comments |
KT-474 (I-417) inhibits IRAK4-mediated IL-6 secretion in R848-stimulated human PBMC with an IC50 <1 nM [1] |